<?xml version="1.0" encoding="UTF-8"?>
<p>In addition to the mentioned treatment benefits, combination PVI/dexamethasone ophthalmic formulation displayed a favorable safety profile and was well tolerated when administered for up to 14 days.
 <xref rid="CIT0093" ref-type="bibr">93</xref> There was also no statistically significant effect on intraocular pressure, as is often associated with topical corticosteroid use. Reported side effects were limited to increased stinging upon instillation when compared to treatment with palliative artificial tears.
 <xref rid="CIT0094" ref-type="bibr">94</xref>
</p>
